Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:502-507
Published online before print January 9, 2003, doi: 10.1161/01.ATV.0000055741.13940.15
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/3/502    most recent
01.ATV.0000055741.13940.15v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharp, R. J.
Right arrow Articles by McCormick, S. P.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharp, R. J.
Right arrow Articles by McCormick, S. P.A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Clinical Studies
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:502.)
© 2003 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

A Synthetic Peptide That Inhibits Lipoprotein(a) Assembly

Rebecca J. Sharp; Matthew A. Perugini; Santica M. Marcovina; Sally P.A. McCormick

From the Department of Biochemistry (R.J.S., S.P.A.M.), University of Otago, Dunedin, New Zealand; Russell Grimwade School of Biochemistry and Molecular Biology (M.A.P.), University of Melbourne, Victoria, Australia; and Department of Medicine (S.M.M.), Northwest Lipid Research Laboratories, University of Washington, Seattle, Wash.

Correspondence to Dr Sally McCormick, Biochemistry Department, University of Otago, 710 Cumberland St, PO Box 56, Dunedin, New Zealand. E-mail sally.mccormick{at}stonebow.otago.ac.nz

Objective— We previously reported that human apolipoprotein B100 (apoB) amino acids 4330–4397 were important for the initial noncovalent binding to apolipoprotein(a) [apo(a)] that facilitates lipoprotein(a) [Lp(a)] assembly. In this study, we aimed to further define the apoB sequences within the 4330–4397 region that were important for the noncovalent binding to apo(a).

Methods and Results— Alignment of the human apoB4330–4397 sequence with mouse apoB, which also noncovalently binds apo(a), revealed stretches of similar sequence, including a lysine-rich sequence spanning apoB amino acids 4372–4392. Structural analysis of the apoB4372–4392 sequence using the WHEEL program predicted an amphipathic {alpha}-helix. Circular dichroism studies of a synthetic peptide spanning human apoB amino acids 4372–4392, both in the absence and presence of dimyristoylphosphatidylcholine, confirmed the {alpha}-helical nature of the sequence. We tested the ability of the apoB4372–4392 peptide to bind to apo(a) and found that the peptide bound to apo(a) with high affinity but not to Lp(a). The apoB4372–4392 peptide inhibited Lp(a) assembly in Lp(a) formation assays far more effectively than the lysine analogue, {epsilon}-amino-n-caproic acid (IC50=40 µmol/L versus 10 mmol/L, respectively). Incorporation of the apoB4372–4392 peptide onto dimyristoylphosphatidylcholine vesicles yielded an even more effective inhibitor (IC50=4 µmol/L).

Conclusions— Our study shows that the apoB4372–4392 sequence mediates the initial noncovalent binding to apo(a) and has demonstrated that the apoB4372–4392 peptide is a novel and effective inhibitor of Lp(a) assembly.


Key Words: lipoprotein(a) • assembly • apolipoprotein B • apolipoprotein(a) • peptide inhibitor




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
Y.-T. Wang, A. von Zychlinski, and S. P. A. McCormick
Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a)
J. Lipid Res., May 1, 2009; 50(5): 846 - 853.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. J. Sharp, M. A. Perugini, S. M. Marcovina, and S. P. A. McCormick
Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein(a) assembly
J. Lipid Res., December 1, 2004; 45(12): 2227 - 2234.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Becker, P. M. Cook, T. G. Wright, and M. L. Koschinsky
Quantitative Evaluation of the Contribution of Weak Lysine-binding Sites Present within Apolipoprotein(a) Kringle IV Types 6-8 to Lipoprotein(a) Assembly
J. Biol. Chem., January 23, 2004; 279(4): 2679 - 2688.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. Y. Y. Liu, R. Broadhurst, S. M. Marcovina, and S. P. A. McCormick
Mutation of lysine residues in apolipoprotein B-100 causes defective lipoprotein[a] formation
J. Lipid Res., January 1, 2004; 45(1): 63 - 70.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
Clin. Chem., November 1, 2003; 49(11): 1785 - 1796.
[Abstract] [Full Text] [PDF]